Shire reports positive data from Phase III trial of Intuniv for ADHD

Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder ( …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news